Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Apr 27, 2015
Apr 24, 2015
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers
Apr 30, 2015 at 9:00 AM ET
May 7, 2015 at 9:20 AM ET